e TIDES trial and played a role in helping us move closer to a dengue-free world.”

Takeda continues to invest in post-marketing research through real-world evidence generation and ongoing pharmacovigilance to deepen understanding of the vaccine’s safety and impact. This includes an Impact Study in the municipality of Dourados, Brazil in partnership with the Dourados Health Department and a Brazilian researcher, as well as the DEN-401 study, an observational, post-authorization effectiveness study of QDENGA in children and adolescents in Southeast Asia.

Since its first approval in Indonesia in 2022, QDENGA has been authorized in 41 countries and 18.6 million doses have been distributed in 11 endemic countries as of September 2025. The World Health Organization added QDENGA to itsList of Prequalified Vaccinesunderscoring its quality and suitability for public vaccination programs to help address the global dengue threat.

These data were presented
=*=*=*=*=*=
当前为第4/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页